Evidence map›Paper›PMID 24958266›Full record

ArticleMetabolites2013

Metabolomics for secondary metabolite research.

Rainer Breitling, Ana Ceniceros, Andris Jankevics, Eriko Takano

Abstract read
In one paragraph

Article in Metabolites, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Quorum sensing gene regulation inFrontiers in microbiology · 2023
    Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Synthetic biology advances for pharmaceutical production.Current opinion in biotechnology · 2015
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Rainer BreitlingManchester Institute of Biotechnology, University of Manchester, 131 Princess Street, Manchester M1 7DN, UK. rainer.breitling@manchester.ac.uk.
Ana CenicerosMicrobial Physiology, Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, Nijenborg 7, Groningen 9747 AG, The Netherlands. a.ceniceros@rug.nl.
Andris JankevicsManchester Institute of Biotechnology, University of Manchester, 131 Princess Street, Manchester M1 7DN, UK. andris.jankevics@manchester.ac.uk.
Eriko TakanoManchester Institute of Biotechnology, University of Manchester, 131 Princess Street, Manchester M1 7DN, UK. eriko.takano@manchester.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolomics, the global characterization of metabolite profiles, is becoming an increasingly powerful tool for research on secondary metabolite discovery and production. In this review we discuss examples of recent technological advances and biological applications of metabolomics in the search for chemical novelty and the engineered production of bioactive secondary metabolites.

Identifiers

PMID24958266
PMCPMC3937839

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.